市场调查报告书
商品编码
1368717
旅行疫苗市场规模- 按成分(单一和组合疫苗)、疾病类型(甲型和乙型肝炎、流感、百白破、黄热病、脑膜炎球菌、伤寒、狂犬病、麻疹和腮腺炎)、应用、全球预测,2023-2032年Travel Vaccines Market Size - By Composition (Mono & Combination Vaccines), Disease Type (Hepatitis A & B, Influenza, DPT, Yellow Fever, Meningococcal, Typhoid, Rabies, Measles & Mumps), Application, Global Forecast, 2023-2032 |
受麻疹和登革热等几种新传染病的涌入和现有传染病死灰復燃的推动,旅行疫苗市场规模从 2023 年到 2032 年的复合年增长率预计将达到 9.7%。根据疾病管制与预防中心的数据,2021 年麻疹估计导致 128,000 人死亡,其中大部分是儿童。
旨在改进现有旅行疫苗和开发新疫苗的持续研发活动和投资也将有助于产业成长。举例来说,2023年5月,巴伐利亚北欧公司投资2.74亿美元收购Emergent BioSolutions的旅游疫苗组合,以加强其研发和製造能力。人们越来越关注创造更方便的单剂量疫苗以提供更广泛的保护,这也将增加产品的采用。
整个旅行疫苗产业根据成分、疾病类型、应用和地区进行细分。
就成分而言,2023-2032年组合旅行疫苗的需求可能会出现可观的复合年增长率。组合疫苗用于简化疫苗接种过程并提高旅行者的依从性。这些疫苗对于在不同地区有接触多种传染病风险的旅客特别有益,因为它们限制了多次疫苗接种的需要,同时提供了对多种疾病的保护。消费者越来越倾向于减少所需的注射和注射次数,这也将有利于产品的吸收。
就疾病类型而言,预计到2032 年,乙型肝炎细分市场的旅游疫苗市场将实现显着的复合年增长率。随着医疗旅游业的快速增长,医疗机构越来越重视患者和医疗游客对乙型肝炎疫苗的需求。限制感染传播。乙型肝炎盛行率较高(主要在非洲和亚洲),加上与工作相关的旅行率上升,将推动该细分市场的成长。根据世界卫生组织的数据,2022 年将有近 9,100 万非洲人感染B型或C型肝炎。
从地区来看,由于中产阶级人口的快速增长和对国际旅行的偏好不断增加,预计到 2032 年,亚太地区旅行疫苗市场规模将出现可观的复合年增长率。该地区多个政府正在不断审查和更新与旅游疫苗相关的法规,例如入境要求和疫苗接种证明。医疗保健组织对旅游疫苗重要性的日益重视也将有利于区域市场的扩张。
Travel Vaccines Market size is poised to record 9.7% CAGR from 2023-2032, driven by the influx of several new infectious diseases and the resurgence of existing ones, including measles and dengue. As per the Centers for Disease Control and Prevention, measles killed an estimated 128,000 people, mostly children in 2021.
The ongoing R&D activities and investments aimed at improving the existing travel vaccines and developing new vaccines will also assist the industry growth. To cite an instance, in May 2023, Bavarian Nordic invested $274M to acquire travel vaccine portfolio of Emergent BioSolutions in a bid to strengthen its R&D and manufacturing capabilities. The growing focus on the creation of more convenient, single-dose vaccines to offer broader protection will also add to the product adoption.
The overall travel vaccines industry is segmented based on composition, disease type, application, and region.
In terms of composition, the demand for combination travel vaccines may record appreciable CAGR from 2023-2032. Combination vaccines are used for simplifying the vaccination process and enhance compliance among travelers. These vaccines are especially beneficial for travelers at risk of exposure to several infectious diseases in different regions as they limit the need for multiple vaccinations while rendering protection against multiple diseases. The rising consumer preference for reducing the number of required injections and shots will also prove favorable for the product uptake.
With respect to disease type, the travel vaccines market from the hepatitis B segment is expected to garner significant CAGR through 2032. With the rapid growth in medical tourism, healthcare facilities are highlighting the requirement for hepatitis B vaccines for patients as well as medical tourists to limit the infection transmission. The higher prevalence of hepatitis B, mainly in Africa and Asia along with the rising rate of work-related travel will drive the segment growth. As per the WHO, nearly 91 million Africans were infected with Hepatitis B or C in 2022.
Regionally, APAC travel vaccines market size is projected to record appreciable CAGR through 2032 due to the rapid growth of the middle-class population and the rising preference for international travel. Several governments in the region are constantly reviewing and updating regulations related to travel vaccines, such as entry requirements and vaccination certificates. The surging emphasis laid by healthcare organizations about the importance of travel vaccinations will also prove favorable for the regional market expansion.